Gesynta Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.gesynta.se
Clinical Trials
7
Active:3
Completed:4
Trial Phases
2 Phases
Phase 1:5
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 2
2 (28.6%)A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Gesynta Pharma AB
- Target Recruit Count
- 94
- Registration Number
- NCT04744207
- Locations
- 🇬🇧
Investigator site, Manchester, United Kingdom
🇬🇧Investigator Site, London, United Kingdom
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
Phase 1
Completed
- Conditions
- Pharmacokinetic
- Interventions
- Drug: Formulation A GS-248Drug: Formulation B GS-248
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Gesynta Pharma AB
- Target Recruit Count
- 14
- Registration Number
- NCT04617509
- Locations
- 🇸🇪
Clinical Trial Consultants AB, Uppsala, Sweden
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Gesynta Pharma AB
- Target Recruit Count
- 72
- Registration Number
- NCT04036227
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
News
No news found